Breast cancer anti-estrogen resistance 3 (BCAR3) is a also known as AND-34/BCAR3/NSP2 (BCAR3). Breast tumors are initially dependent on estrogens for growth and progression and can be inhibited by anti-estrogens such as tamoxifen. However, breast cancers progress to become anti-estrogen resistant. BCAR3 was identified in the search for genes involved in the development of estrogen resistance. The gene encodes a component of intracellular signal transduction that causes estrogen-independent prolifeRation in Human breast cancer cells. The protein contains a putative src homology 2 (SH2) domain, a hall mark of cellular tyrosine kinase signaling molecules, and is partly homologous to the cell division cycle protein CDC48
应用类型
Enzyme-linked immunosorbent assay|Flow cytometry|Immunohistochemistry|Immunoprecipitation|Western blot
免疫原
A synthetic peptide surrounding of RHIMDR-T*-PEKLK of human BCAR3 protein with a single phosphorylation site at Thr 130. This sequence is identical to human, rat, mouse, canis and bovine.
来源宿主
Rabbit
反应性
该Anti-BCAR3 抗体 (Phospho-T130)的反应性请参考该产品的说明书
保存建议
The antibodies are stable for 24 months from date of receipt when stored at -20C to -70C. The antibodies can be stored at 2C-8C for three month without detectable loss of activity. Avoid repeated freezing-thawing cycles.
其他
Aviva Systems Biology总部位于加利福尼亚州圣迭戈，在中国北京设有办公室，专注于为研究需求提供多克隆和单克隆抗体、ELISA试剂盒、蛋白质和定制服务。Aviva Systems Biology生产了24,000种经过验证的多克隆抗体，并提供近20,000种ELISA试剂盒，定制实验室服务包括蛋白表达和纯化、抗体开发，以及ELISA的开发、验证和生产。Aviva Systems Biology为与独特物种和靶标相关的研究提供独特工具，研究领域包括转录因子、癌症、心血管、细胞生物学、DNA损伤和修复、表观遗传学、信号转导、细胞分化、干细胞生物学等等。
